Recent Finacing
Recent Raise
CEVEC develops proprietary cell-line platforms—ELEVECTA for stable AAV producer cell lines and CAP/CAP-Go for RCA-free adenoviral production and complex recombinant protein expression, now expanding HEK293 use.
Focus Areas
Recent Investors
Funding round
Investor